Integrins (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database by Farndale, Richard W. & Jarvis, Gavin E.
IUPHAR/BPS Guide to Pharmacology CITE
https://doi.org/10.2218/gtopdb/F760/2019.4
Integrins (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology
Database
Richard W. Farndale1 and Gavin E. Jarvis1
1. University of Cambridge, UK
Abstract
Integrins are unusual signalling proteins that function to signal both from the extracellular environment into the
cell, but also from the cytoplasm to the external of the cell. The intracellular signalling cascades associated with
integrin activation focus on protein kinase activities, such as focal adhesion kinase and Src. Based on this
association between extracellular signals and intracellular protein kinase activity, we have chosen to include
integrins in the 'Catalytic receptors' section of the database until more stringent criteria from NC-IUPHAR allows
precise definition of their classification.
Integrins are heterodimeric entities, composed of α and β subunits, each 1TM proteins, which bind components
of the extracellular matrix or counter-receptors expressed on other cells. One class of integrin contains an
inserted domain (I) in its α subunit, and if present (in α1, α2, α10, α11, αD, αE, αL, αM and αX), this I
domain contains the ligand binding site. All β subunits possess a similar I-like domain, which has the capacity to
bind ligand, often recognising the RGD motif. The presence of an α subunit I domain precludes ligand binding
through the β subunit. Integrins provide a link between ligand and the actin cytoskeleton (through typically short
intracellular domains). Integrins bind several divalent cations, including a Mg2+ ion in the I or I-like domain that
is essential for ligand binding. Other cation binding sites may regulate integrin activity or stabilise the 3D
structure. Integrins regulate the activity of particular protein kinases, including focal adhesion kinase and
integrin-linked kinase. Cellular activation regulates integrin ligand affinity via inside-out signalling and ligand
binding to integrins can regulate cellular activity via outside-in signalling.
Several drugs that target integrins are in clinical use including: (1) abciximab (αIIbβ3) for short term prevention
of coronary thrombosis, (2) vedolizumab (α4β7) to reduce gastrointestinal inflammation, and (3) natalizumab
(α4β1) in some cases of severe multiple sclerosis.
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This is a citation summary for Integrins in the Guide to Pharmacology database (GtoPdb). It exists purely as an
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Readers will almost certainly want to visit the relevant sections of the database which are given here under
database links.
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Please note that the database version for the citations given in GtoPdb are to the most recent preceding version
in which the family or its subfamilies and targets were substantially changed. The links below are to the current





    Receptors
        Complexes
            integrin α1β1
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2577
            integrin α2β1
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2578
            integrin αIIbβ3
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2579
            integrin α4β1
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2580
            integrin α4β7
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2770
            integrin α5β1
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2581
            integrin α6β1
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2867
            integrin α10β1
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2868
            integrin α11β1
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2869
            integrin αEβ7
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2799
            integrin αLβ2
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2582
            integrin αVβ3
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2583
        Receptors and Subunits
            integrin, alpha 1 subunit
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2437
            integrin, alpha 2 subunit (CD49B, alpha 2 subunit of VLA-2 receptor)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2440
            integrin, alpha IIb subunit (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2441
            integrin, alpha 3 subunit (antigen CD49C, alpha 3 subunit of VLA-3 receptor)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2442
            integrin, alpha 4 subunit (antigen CD49D, alpha 4 subunit of VLA-4 receptor)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2443
            integrin, alpha 5 subunit (fibronectin receptor, alpha polypeptide)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2444
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            integrin, alpha 6 subunit
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2445
            integrin, alpha 7 subunit
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2446
            integrin, alpha 8 subunit
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2447
            integrin, alpha 9 subunit
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2448
            integrin, alpha 10 subunit
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2438
            integrin, alpha 11 subunit
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2439
            integrin, alpha D subunit
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2449
            integrin, alpha E subunit (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2450
            integrin, alpha L subunit (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha
polypeptide)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2451
            integrin, alpha M subunit (complement component 3 receptor 3 subunit)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2452
            integrin, alpha V subunit
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2453
            integrin, alpha X subunit (complement component 3 receptor 4 subunit)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2454
            integrin, beta 1 subunit (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2455
            integrin, beta 2 subunit (complement component 3 receptor 3 and 4 subunit)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2456
            integrin, beta 3 subunit (platelet glycoprotein IIIa, antigen CD61)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2457
            integrin, beta 4 subunit
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2458
            integrin, beta 5 subunit
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2459
            integrin, beta 6 subunit
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2460
            integrin, beta 7 subunit
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2461
            integrin, beta 8 subunit
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2462
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